Financial Performance - The company's revenue for Q3 2021 reached ¥116,982,844.81, representing a 48.40% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2021 was ¥26,167,007.78, a significant increase of 158.41% compared to the same period last year[5] - The basic and diluted earnings per share for Q3 2021 were both ¥0.33, reflecting a 94.12% increase year-over-year[9] - Total operating revenue for the first three quarters of 2021 reached ¥341,097,584.39, a 45.3% increase compared to ¥234,530,370.00 in the same period of 2020[37] - Net profit for the third quarter of 2021 was ¥86,949,842.52, compared to ¥51,885,173.34 in the same quarter of 2020, representing a 67.6% increase[39] - Basic earnings per share for the third quarter of 2021 were ¥1.42, up from ¥0.85 in the same quarter of 2020, indicating a 67.1% increase[42] - The total comprehensive income for the third quarter of 2021 was ¥86,949,842.52, compared to ¥51,885,173.34 in the same quarter of 2020, reflecting a 67.6% increase[42] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥1,016,403,557.08, marking a 164.10% increase from the end of the previous year[9] - The company's total assets as of September 30, 2021, were ¥1,016,403,557.08, compared to ¥384,855,194.54 at the end of 2020, marking an increase of about 164.5%[31] - Total liabilities increased to ¥245,817,987.18 from ¥191,936,883.15, which is an increase of approximately 28.0%[30] - Total liabilities amounted to ¥268,603,910.72, compared to ¥191,936,883.15 in the previous year, reflecting a 39.8% increase[37] - Current liabilities totaled 191,936,883.15, with accounts payable at 13,628,176.02 and contract liabilities at 128,292,304.80[54] Equity and Shareholder Information - The company's total equity attributable to shareholders increased to ¥741,418,402.25, a 292.07% rise from the previous year[9] - Total equity attributable to shareholders reached ¥741,418,402.25, significantly up from ¥189,104,685.80 in 2020, indicating a growth of 292.5%[37] - The number of common shareholders at the end of the reporting period was 80,000,000, with the largest shareholder holding 27.59% of the shares[18] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder owning 22,069,500 shares[18] Research and Development - The company's R&D expenditure for Q3 2021 was ¥15,901,438.13, which is a 121.01% increase compared to the same period last year[9] - The proportion of R&D expenditure to revenue for Q3 2021 was 13.59%, an increase of 4.47 percentage points year-over-year[9] - Research and development expenses for the first three quarters of 2021 totaled ¥35,676,542.07, compared to ¥19,935,145.21 in 2020, marking an increase of 78.9%[37] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥45,583,455.19, showing a slight decrease of 3.83% compared to the previous year[5] - Operating cash inflow for the first three quarters of 2021 was CNY 306,782,145.65, an increase of 28.1% compared to CNY 239,500,900.54 in the same period of 2020[46] - Cash outflow from operating activities totaled CNY 261,198,690.46, up 36.0% from CNY 192,101,184.75 year-on-year[46] - Cash inflow from investment activities was CNY 809,869.59, significantly lower than CNY 6,002,136.99 in the same period last year[49] - Cash outflow from investment activities surged to CNY 350,925,853.99, compared to CNY 66,052,490.99 in the previous year[49] - Net cash flow from financing activities was CNY 466,509,710.76, a substantial increase from a net outflow of CNY 2,785,689.40 in the same period last year[49] Other Financial Information - The company reported a financial expense of ¥1,212,540.52 for the third quarter of 2021, an increase from ¥830,809.45 in the same quarter of 2020[37] - The company’s investment income for the third quarter of 2021 was ¥567,205.55, compared to ¥2,136.99 in the same quarter of 2020[37] - The company has a long-term equity investment valued at ¥40,000,000.00 as of September 30, 2021[28] - The company implemented new leasing standards starting January 1, 2021, affecting the financial statements[57] - The company did not adjust comparative period information for the initial application of the new leasing standards[57]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2021, representing a 20% increase compared to the same period last year[2]. - The company reported a revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[19]. - The company achieved operating revenue of CNY 224.11 million in the first half of 2021, representing a year-on-year growth of 43.94%[34]. - The total revenue for the company reached approximately 270.67 million RMB, with a net profit of around 53.33 million RMB, reflecting a significant performance in the first half of 2021[89]. - The company reported a significant increase in cash and cash equivalents to RMB 584.10 million, up 434.37% from the previous year[131]. - The net profit attributable to shareholders was CNY 58.97 million, an increase of 44.35% compared to the same period last year[37]. - The net profit reached RMB 60.31 million, reflecting a growth of 50.15% compared to the previous year[123]. - The company reported a net profit margin of 20% for the first half of 2021, an improvement from 15% in the same period last year[169]. User and Market Growth - User data showed an increase in active users by 15%, reaching 1.2 million users by the end of June 2021[2]. - User data showed an increase in active clients by 15%, reaching a total of 1,200 clients by June 30, 2021[19]. - User data showed a growth in active users, reaching 2 million, which is a 40% increase year-over-year[169]. - The company expects a revenue growth of 25% for the second half of 2021, driven by new product launches and market expansion strategies[19]. - The company provided a forward guidance of 10% revenue growth for the second half of 2021, projecting total revenue to reach 550 million RMB[2]. - Market expansion plans include entering three new international markets by the end of 2021, projected to contribute an additional $100 million in revenue[169]. Research and Development - The company invested 100 million RMB in R&D for new technologies, focusing on innovative drug development[2]. - Investment in R&D increased by 30% compared to the previous year, focusing on innovative drug development and clinical trials[19]. - The R&D investment accounted for 8.82% of operating revenue, an increase of 0.64 percentage points compared to the previous year[33]. - The company has established advanced technology platforms in drug discovery, pharmaceutical research, clinical trials, and bioanalysis, ensuring compliance with global regulatory standards[62]. - The company has over 80 ongoing research projects in innovative drugs, with a focus on pain relief, kidney disease, oncology, cardiovascular, and antibacterial treatments[69]. - The company is focusing on innovative drugs for pain relief, kidney disease, oncology, cardiovascular, and antibacterial applications, which are expected to drive future growth[66]. - The company has initiated a new strategy focusing on digital transformation to enhance operational efficiency and customer engagement[19]. Product Development and Launches - New product launches contributed to 30% of total revenue, with three new drugs introduced in the market during the first half of 2021[2]. - A new partnership was announced with a leading pharmaceutical company to enhance drug development capabilities and accelerate time-to-market[19]. - The company is focusing on developing long-acting formulations and controlled-release systems in its innovative drug pipeline[69]. - The company is also working on complex generics and pediatric medications, targeting rare diseases and other special formulations[69]. Financial Management and Investments - The company signed new orders worth CNY 439 million in the first half of 2021, a year-on-year increase of 68.85%[34]. - The company has committed to implementing investment projects funded by the raised capital to achieve expected returns as soon as possible[197]. - The company has established a fundraising management method to ensure that raised funds are used specifically for designated projects, enhancing regulatory oversight[197]. - The company has established a detailed profit distribution mechanism to ensure stable and sustainable returns for investors, including conditions for cash dividends and stock dividends[197]. Corporate Governance and Compliance - There were no significant changes in corporate governance arrangements during the reporting period[2]. - The company has established internal systems for environmental protection and pollution management, ensuring compliance with relevant standards[159]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[160]. - The company held its annual general meeting on April 15, 2021, with all proposals approved and no dissenting votes[153]. Risks and Challenges - The company faces risks related to rapid technological advancements in drug development, which may require significant investment in new technologies and talent[114]. - There is a risk of core technical talent loss and leakage of proprietary technology, which could adversely affect the company's competitive position and profitability[115]. - Increased competition in the CRO market from both domestic and international players poses a challenge to the company's market expansion efforts[117]. - The company operates in a high-risk, long-cycle industry, with potential execution risks associated with long-term contracts[121].